Pelthos Therapeutics Inc.
AMEX:PTHSBiotechnology
-$0.37 today
- Market cap
- $63.32M
- Beta
- 3.13
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$15.58
Volume 0.01M
Average 0.04M
PTHS Short-term Debt
Borrowings and the current portion of long-term debt due within one year.
Pelthos Therapeutics Inc.AMEX: PTHS
Short-term Debt · Q1 FY2026 · quarter ended Mar 2026
Short-term debt falls 74.4% from a year ago
Short-term debt stood at $640K at the end of Q1 FY2026, down 74.4% from a year earlier and up 0.8% from the prior quarter. Over 3 fiscal years it compounded at +5.5% a year.
Context
- Short-term debt amounted to 0.4% of total assets at the end of Q1 FY2026, down 274.3 pp from a year earlier.
- Short-term debt increased in 2 of the last 3 fiscal years.
What to watch
Whether short-term debt keeps falling in the next quarterly balance sheet after a -74.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Debt history
USD · from the balance sheet
- Latest · FY2025
- 635K USD
- Year-over-year change
- -71.0%
- 3-year CAGR
- +5.5%
| Period | Period end | Short-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 635K | -71.0% |
| FY2024 | 2024-12-31 | 2.19M | +72.3% |
| FY2023 | 2023-12-31 | 1.27M | +134.8% |
| FY2022 | 2022-12-31 | 540.43K | — |
Short-term Debt vs competitors
How PTHS compares with its peers on the latest reported figures
- PTHS's Mar 2026 short-term debt of $640K is the 2nd highest of the 4 companies compared; the peer median is $595.42K.
- Its year-over-year change of -74.4% is the lowest of 2, against a peer median of +49.0%.
- Short-term debt amounts to 0.4% of total assets for PTHS, versus a peer median of 5.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $6.15M | +49.0% | +8.0% | 19.9% | |
| Mar 2026 | $640K | -74.4% | +5.5% | 0.4% | |
| Mar 2026 | $595.42K | — | — | 5.5% | |
| Dec 2025 | $0 | — | — | 0.0% | |
| Peer median (excluding PTHS) | $595.42K | +49.0% | +8.0% | 5.5% | |
Competitors are the stored peer set for PTHS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Pelthos Therapeutics Inc.
AMEX:PTHS
Intrinsic Alpha fair value
Locked
Current Price
$16.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.